Meridian Bioscience Balance Sheet Health
Financial Health criteria checks 6/6
Meridian Bioscience has a total shareholder equity of $368.1M and total debt of $25.0M, which brings its debt-to-equity ratio to 6.8%. Its total assets and total liabilities are $463.1M and $95.0M respectively. Meridian Bioscience's EBIT is $75.6M making its interest coverage ratio 64.5. It has cash and short-term investments of $81.5M.
Key information
6.8%
Debt to equity ratio
US$25.00m
Debt
| Interest coverage ratio | 64.5x |
| Cash | US$81.45m |
| Equity | US$368.06m |
| Total liabilities | US$95.04m |
| Total assets | US$463.10m |
Recent financial health updates
Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet
Jun 27
These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely
Jul 19Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly
Mar 31Recent updates
Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M
Aug 05Meridian Bioscience: High-Probability Merger Arbitrage
Jul 26Meridian Bioscience downgraded at William Blair on $1.53B acquisition
Jul 07Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet
Jun 27Meridian Bioscience: Correctly Valued
Jun 26Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital
Jun 09Meridian Bioscience: Deceptively Priced
Mar 14Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns
Feb 03These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely
Jul 19If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy
Jul 08Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine
May 10Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation
May 08Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly
Mar 31Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?
Mar 11Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%
Feb 24Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues
Feb 09
Meridian expands production capacity for COVID-19 tests with NIH funding
Feb 03Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?
Jan 27Financial Position Analysis
Short Term Liabilities: VIVO's short term assets ($210.6M) exceed its short term liabilities ($58.0M).
Long Term Liabilities: VIVO's short term assets ($210.6M) exceed its long term liabilities ($37.1M).
Debt to Equity History and Analysis
Debt Level: VIVO has more cash than its total debt.
Reducing Debt: VIVO's debt to equity ratio has reduced from 32.2% to 6.8% over the past 5 years.
Debt Coverage: VIVO's debt is well covered by operating cash flow (329.4%).
Interest Coverage: VIVO's interest payments on its debt are well covered by EBIT (64.5x coverage).